Control Bionics Limited (CBL.AX)

AUD 0.06

(-1.69%)

Market Cap (In AUD)

14.35 Million

Revenue (In AUD)

5.12 Million

Net Income (In AUD)

-5.91 Million

Avg. Volume

214.75 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.038-0.105
PE
-
EPS
-
Beta Value
0.172
ISIN
AU0000114183
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Jeremy E. Steele
Employee Count
-
Website
https://www.controlbionics.com
Ipo Date
2020-12-06
Details
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Camberwell, Australia.